Literature DB >> 29536169

[Intraocular inflammation in multiple sclerosis].

N Stübiger1, K Ruprecht2, U Pleyer3.   

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disorder of the brain and the spinal cord occurring mostly in young adults and is associated with temporary or permanent neurological deficits. An association between uveitis and MS has been recognized for a long time. Current data indicate an approximately 10 times higher prevalence of uveitis in patients with MS compared to the general population. In particular, MS is associated with intermediate uveitis and typically with concomitant retinal vasculitis. The treatment of uveitis should not only take the severity of intraocular inflammation into account but a coordination of the active agents must also consider the neurological manifestations. Since uveitis and MS are pathogenetically based on an immune-mediated genesis, immunomodulatory treatment approaches are dominant but it is important to bear in mind that tumor necrosis factor(TNF)-alpha blocking agents may worsen MS.

Entities:  

Keywords:  Concomitant vasculitis; Epidemiology; Immunomodulation; Treatment; Uveitis

Mesh:

Substances:

Year:  2018        PMID: 29536169     DOI: 10.1007/s00347-018-0673-5

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  56 in total

1.  Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats.

Authors:  S Kurose; E Ikeda; M Tokiwa; N Hikita; M Mochizuki
Journal:  Exp Eye Res       Date:  2000-01       Impact factor: 3.467

2.  Intermediate uveitis and multiple sclerosis: to scan or not to scan.

Authors:  Harry Petrushkin; Desmond Kidd; Carlos Pavesio
Journal:  Br J Ophthalmol       Date:  2015-09-02       Impact factor: 4.638

Review 3.  Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis.

Authors:  Richard Nicholas; Sebastian Straube; Heinz Schmidli; Sebastian Pfeiffer; Tim Friede
Journal:  Mult Scler       Date:  2012-03-15       Impact factor: 6.312

Review 4.  Fingolimod-associated macular edema: incidence, detection, and management.

Authors:  Nieraj Jain; M Tariq Bhatti
Journal:  Neurology       Date:  2012-02-28       Impact factor: 9.910

Review 5.  Sheathing of the retinal veins in multiple sclerosis. Review of pertinent literature.

Authors:  C W Rucker
Journal:  Mayo Clin Proc       Date:  1972-05       Impact factor: 7.616

6.  Crucial role of CCL3/MIP-1alpha in the recurrence of autoimmune anterior uveitis induced with myelin basic protein in Lewis rats.

Authors:  Maria Manczak; Shuguang Jiang; Beata Orzechowska; Grazyna Adamus
Journal:  J Autoimmun       Date:  2002-06       Impact factor: 7.094

7.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

8.  Uveitis as a prognostic factor in multiple sclerosis.

Authors:  Erkingul Shugaiv; Erdem Tüzün; Murat Kürtüncü; Aslı Kıyat-Atamer; Arzu Çoban; Gulsen Akman-Demir; Ilknur Tugal-Tutkun; Mefkure Eraksoy
Journal:  Mult Scler       Date:  2014-06-16       Impact factor: 6.312

Review 9.  [A case of multiple sclerosis associated with granulomatous panuveitis].

Authors:  F Moriwaka; K Tashiro; T Fukazawa; R Miyagishi; Y Sasamoto
Journal:  Rinsho Shinkeigaku       Date:  1994-07

Review 10.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

View more
  2 in total

Review 1.  [Guidelines nr. 24a intermediate uveitis].

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

Review 2.  Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges.

Authors:  Horace Massa; Spyros Y Pipis; Georgios D Panos; Temilade Adewoyin; Athanasios Vergados; Sudeshna Patra
Journal:  Clin Ophthalmol       Date:  2019-09-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.